Category list : All-Wales Medicines Strategy Group
Sort by: Newest first Oldest first A-Z Z-A
-
Restrictions on prescribing OTC treatments rejected in Wales
Proposals to restrict the prescribing of medicines and other treatments that are available over the counter will not go ahead in Wales.
-
Three-year PrEP pilot begins in Wales
A trial has begun in Wales to assess the use of the antiretroviral combination treatment emtricitabine/tenofovir disoproxil (marketed as Truvada) for pre-exposure prophylaxis (PrEP) against HIV infection.
-
Treatment fund launched in Wales for newly approved drugs
An £80m new treatment fund to pay for high-cost drugs approved for use on the NHS in Wales has been launched.
-
Welsh audit body recommends managing medicines plan
The government, the NHS and health bodies should revise the indicators used to compare how different prescribers and organisations use medicines, says a report by the Welsh Audit Office.
-
Gething confirms £80m fund for high-cost medicines in Wales
A central fund worth £80m that will pay for the immediate use of new, high-cost medicines that are approved for use in Wales has been announced by Vaughan Gething, cabinet secretary for health for the Welsh government.
-
Welsh Labour pledge to create £80m central fund for high cost drugs Subscription
Welsh Labour has pledged to create an £80m central fund to pay for high cost medicines if they retain control of the National Assembly for Wales following the election on 5 May 2016.
-
January 2016: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use by the NHS in Wales: atazanavir/cobicistat (Evotaz) for adults infected with human immunodeficiency virus-1 (HIV-1); efavirenz (Sustiva) for children aged between 3 months and 3 years who are infected with HIV-1; macitentan (Opsumit) for adults with pulmonary arterial hypertension (only where the approved patient access scheme is used); empagliflozin (Jardiance) for type 2 diabetes. Full details ...
-
December 2015: AWMSG approvals Subscription
The All Wales Medicines Strategy Group (AWMSG) has approved the following medicines for use in NHS Wales: Cetuximab (Erbitux; Merck Serono) for the first-line treatment of epidermal growth factor receptor-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan-based chemotherapy or the chemotherapy regimen FOLFOX. Ivacaftor (Kalydeco; Vertex) for cystic fibrosis (CF) in patients aged 6 years and older who have mutations in the CF transmembrane ...
-
December 2015: AWSMG approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Abasaglar (a biosimilar of insulin glargine; Eli Lilly and Company) for diabetes mellitus in patients aged 2 years and above. Sucroferric oxyhydroxide (Velphoro; Vifor Fresenius Medical Care Renal Pharma) for controlling serum phosphorus levels in adults with chronic kidney disease who are on haemodialysis or peritoneal dialysis where non-calcium based ...
-
AWMSG November medicines approvals Subscription
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Xultophy (insulin degludec and liraglutide) for use with oral antidiabetic drugs to treat adults with type 2 diabetes — it can only be used when oral treatments combined with basal insulin do not provide adequate glycaemic control; Fomicyt (fosfomycin) to treat acute osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections or bacterial ...
Show 10 per page20 per page50 per page
